Appearance of bone marrow lymphocytosis predicts an optimal response to imatinib therapy in patients with chronic myeloid leukemia (Q61776736)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17568811%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

title

Appearance of bone marrow lymphocytosis predicts an optimal response to imatinib therapy in patients with chronic myeloid leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17568811%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

0 references

1 reference

chronic myeloid leukemia

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17568811%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Kimmo Porkka

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17568811%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

Lundán T

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17568811%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Knuutila S

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17568811%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

publication date

14 June 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17568811%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17568811%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17568811%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17568811%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

2363-2368

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17568811%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404807

31 December 2019

exact match

0 references

cites work

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404807

7 January 2021

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404807

7 January 2021

Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404807

7 January 2021

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404807

7 January 2021

Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404807

7 January 2021

Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404807

7 January 2021